Most importantly, since several selective inhibitors of CD73 are now available and have entered clinical trials [20, 21], targeting CD73 combined with immune checkpoint blockades or chemotherapy in preclinical animal ICC models will provide more solid evidence. The gene discussed is NT5E; the disease is intrahepatic cholangiocarcinoma.